Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults
Jaya Goswami, Abdullah H Baqui, Pablo Alexis Doreski, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 5, pp. e996-e1006
Open Access | Times Cited: 12

Showing 12 citing articles:

Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies
Natalie I Mazur, Mauricio T. Caballero, Marta C. Nunes
The Lancet (2024) Vol. 404, Iss. 10458, pp. 1143-1156
Closed Access | Times Cited: 15
The recent landscape of RSV vaccine research
Karen Kelleher, N. Subramaniam, Simon B. Drysdale
Therapeutic Advances in Vaccines and Immunotherapy (2025) Vol. 13
Open Access | Times Cited: 1
Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines
Cleo Anastassopoulou, Snežana Medić, Stefanos Ferous, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 97-97
Open Access
Plattformtechnologien in der Impfstoffentwicklung
Eberhard Hildt
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2025)
Open Access
A bivalent mRNA vaccine against RSV infection in rodent models
Juan Liu, Hanqing Zhao, Wenhao Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial
Jaya Goswami, José F. Cardona, Denise C. Hsu, et al.
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 3
Cracking the Codes behind Cancer Cells’ Immune Evasion
Nikita Mundhara, Pritam Sadhukhan
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8899-8899
Open Access | Times Cited: 1
mRNA medicine: Recent progresses in chemical modification, design, and engineering
Xiaowen Hou, Jinjun Shi, Yuling Xiao
Nano Research (2024) Vol. 17, Iss. 10, pp. 9015-9030
Closed Access
Immune Responses to Respiratory Syncytial Virus Vaccines: Advances and Challenges
Gabriela Souza da Silva, Sofia Giacomet Borges, Bruna Bastos Pozzebon, et al.
Microorganisms (2024) Vol. 12, Iss. 11, pp. 2305-2305
Open Access
Respiratory Syncytial Virus Vaccine (mRNA)
Terri Levien, Danial E. Baker
Hospital Pharmacy (2024)
Closed Access
Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue
Qianqian Li, Huan Li, Zhihua Li, et al.
MedComm (2024) Vol. 5, Iss. 12
Open Access
Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options
Matteo Riccò, Bahaa Abu-Raya, Giancarlo Icardi, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1317-1317
Open Access
Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus
Christine A. Shaw, Guillaume B. E. Stewart-Jones, Patricia A. Jorquera, et al.
Research Square (Research Square) (2024)
Closed Access
Page 1

Scroll to top